No Data
Chinese Drug Regulator Accepts Hengrui Medicine's Marketing Application for Children's Eye Drops
Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for the上市 license of the pharmaceutical Emmaxitinib ointment has been accepted.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company received a notice from the National Medical Products Administration ("National Drug...")
Hengrui Medicine Gets Approval for Spondyloarthritis Clinical Trials
Jiangsu Hengrui Pharmaceuticals (600276.SH): Received the approval notice for drug clinical trial.
On February 13, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya Biomedical Co., Ltd. has received the approval notice for clinical trials of Fubanqi Zhudankang Injection from the National Medical Products Administration, and clinical trials will be conducted soon. Fubanqi Zhudankang Injection is a recombinant humanized monoclonal antibody targeting human IL-17A independently developed by the company, intended for the treatment of autoimmune diseases related to the IL-17 pathway.
Orient: The market prospects for lipid-lowering drugs are broad, with new targets and new technological routes continually being validated.
Due to the rising incidence of dyslipidemia, which is increasingly affecting younger populations, the market for lipid-lowering drugs has a broad outlook. At the same time, new targets and new technological routes are being continuously validated, and the approval of Innovative Drugs can also drive rapid market expansion.
Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Price In Tune With Earnings
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
